Advancing novel therapy that restores apoptosis in cancers and other diseases

Matariki Bioscience develops drugs to treat cancer and chronic pain

A nano-drug delivery platform for targeted cancer therapy

The next generation oncology therapy

The next generation cancer therapeutics and autoimmune disease were developed by Sutro Biopharma. This company has pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Their focus is aimed primarily on Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, the company can design and develop targeted medicines by innovating outside the constraints of the cell.  The company technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. Their approach to discovery, without the cell, is also transcending the limitations of biologics manufacturing.

by
15 hours ago

Radiolabeled microtubule ligands for central nervous system (CNS) imaging

The microtubule dysregulation is associated with many diseases including cancer (lat. Carcinoma) and neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and ALS, making them an important diagnostic and therapeutic target. PET is a non-invasive molecular imaging technique currently used for in vivo imaging. Although this imaging technique is powerful, imaging the brain is challenging because the radiotracers used must be capable of crossing the blood-brain barrier (BBB). There are currently no PET tracers available for the in vivo imaging of microtubules in the brain. However, scientists, led by Professor J. John Mann, at the Columbia University Medical Center developed a radiolabeled microtubule binding agent that enables positron emission tomography (PET) imaging of microtubules in the brain for diagnosis and treatment monitoring of tumours and neurological disease.

by
15 hours ago

Duplex Sequencing Technology guides therapy at the earliest stages of cancer

Technology, which can detect ultra-rare variants that are invisible by other sequencing approaches, was developed by TwinStrand Biosciences. The company is spinoff of The University of Washington. TwinStrand Biosciences is applying this technology to a new generation of high-accuracy clinical diagnostics and innovative tools for scientific discovery.  Current sequencing methods are error-prone, which precludes the identification of low-frequency mutations for early cancer (lat. Carcinoma) detection. Duplex sequencing is a sequencing technology that decreases errors by scoring mutations present only in both strands of DNA. Duplex Sequencing Technology uses specialized DupSeq to uniquely tag both strands of individual DNA duplexes in a population. This allows identification and comparison of the sequencing read derived from amplified copies of each strand of a particular molecule of origin.

by
15 hours ago

'ViraT' makes cancer immunotherapies more powerful

DNA-templated micelle system for delivery of therapeutic agents

CRISPR Therapeutics provides gene-based medicine

Decibel Therapeutics protects, repairs and restores hearing loss

The novel therapies for people with hearing loss and tinnitus were developed by Decibel Therapeutics. This company is spinoff of Harvard University. Decibel. Approximately 360 million people worldwide are living with hearing loss, and this number continues to grow. This issue has been widely overlooked and under-resourced in medicine, and there are currently no therapeutic options available to address hearing disorders. Furthermore, devices, such as cochlear implants and hearing aids, have limitations. Like most conditions, there are different underlying molecular causes of hearing disorders; therefore, therapeutic interventions need to be matched to the appropriate patient populations based on the underlying cause of their hearing issues.

by
15 hours ago

New drugs for the treatment of autoimmune diseases

Drugs for the treatment of autoimmune diseases were developed by Paragen Bio. The company was founded in Australia. The technology is based on the science from the labs of Drs Alex Loukas, Paul Giacomin, Norelle Daly and Severine Navarro of the Australian Institute of Tropical Health and Medicine at James Cook University. The company brings together a number of leading international medical research teams to develop novel therapeutics that will treat autoimmune diseases, such as inflammatory bowel disease and asthma. Paragen Bio is a biotechnology company developing next-generation biologics for treating disorders that result from a dysfunctional immune system. The drug discovery ethos is underpinned by millennia of host-parasite co-evolution. Hookworms have evolved to survive in their vertebrate hosts while causing minimal pathology, a relationship that has been fine tuned for millions of years.

by
15 hours ago

Principia Biopharma challenges traditional drug discovery

Principia Biopharma is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology (lat. Oncologia). Their proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that will rival those of injectable biologics, yet maintain the convenience of a pill. Principia Biopharma is based on research at the University of California, San Francisco. Standard small molecule drugs have a short residence time and, therefore, require dosing regimens that sustain minimum concentration levels in the blood at all times to maintain beneficial effects on the target. By optimizing for target residence time, their drug candidates remain bound to the target but otherwise clear the body rapidly, as exemplified in the movie below. Scientists believe this minimizes both off-target effects and total exposure of the drug while achieving high clinical benefit.

by
15 hours ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM